Cellectis S.A. (ENXTPA: ALCLS)
Health Care · Biotechnology · FR
€2.87
+5.59% today · +14.3% 1Y
Cellectis S.A. (ENXTPA: ALCLS) operates in the Biotechnology industry within the Health Care sector. The company is valued at $243.57M and employs 227 people.
Over the last twelve months the share price has gained 14.3%, trading between 2.03 and 4.84.
Tweenvest scores Cellectis S.A. across four factors: quality 38/100, value 60/100, growth 50/100. Its strongest factor is value.
ALCLS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $243.57M
- Revenue (TTM)
- $63.82M
- P/E
- —
- EPS
- -0.65
- Dividend yield
- —
- Beta (5Y)
- 2.75
- 52-week high
- €4.84
- 52-week low
- €2.03
- Avg volume (3M)
- —
- Shares outstanding
- 72.70M
- Employees
- 227
- Next earnings
- —
About Cellectis S.A.
Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and headquartered in Paris, France, concentrates on immuno-oncology. The firm engineers therapeutic solutions utilizing gene-edited T-cells, which are modified to display chimeric antigen receptors (CARs) for the specific identification and destruction of cancer cells. Its operations are divided into two principal segments: Therapeutics and Plants. The company's pipeline features several allogeneic CAR T-cell product candidates. These include UCART19, aimed at CD19-expressing hematologic malignancies such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A, developed to treat relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316, targeting renal cell carcinoma; UCART123, for acute myeloid leukemia; and UCART22, addressing B-cell acute lymphoblastic leukemia. Additionally, Cellectis is advancing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. Cellectis has forged significant strategic partnerships and alliances with companies including Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. It also maintains a strategic research and development collaboration with Cytovia Therapeutics, Inc.
- ISIN
- FR0010425595
- Founded
- 1999
- Listed since
- Feb 7, 2007
- Exchange
- Euronext Paris
- Currency
- EUR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $266.66 | +0.64% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $441.00 | +0.38% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.97 | +0.58% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.19 | +0.03% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $842.16 | +0.97% |
| argenx SEENXTBR: ARGX | $65.85B | €875.60 | -2.93% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $144.51 | -0.39% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.